Fennec Pharmaceuticals Releases Q2 2026 Financial Results
Fennec Pharmaceuticals Inc. reported strong Q2 2026 financial results, with diluted earnings of $0.05 per share, significantly beating the $0.01 consensus. The company's revenue reached $17.9M, an 85% increase year-over-year, and net income was $2.0M, a substantial improvement from a loss in the prior …